Amarin Corporation plc
Every calculator, already run for AMRN
Open the full toolkit →You have the numbers on AMRN. Get the argument.
A written report on which of these readings actually decide the outcome for Amarin Corporation plc, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
2 analysts covering AMRNAnalyst Price Target Disagreement for Amarin Corporation plc
Wall Street's bull case implies +8% from the current price; the bear case implies -1%. Analysts are relatively aligned on AMRN's range.
Ownership & short interest
Insider Trading Activity for AMRN
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Amarin Corporation plc
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in…
AMRN — frequently asked
Is AMRN a buy right now?
Wall Street's consensus rating on Amarin Corporation plc is none across 2 analysts, with a mean price target of $12.50 (+4% vs. the current $12.07). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is AMRN's next earnings date?
Amarin Corporation plc is next scheduled to report earnings around Oct 28, 2026. A full AMRN research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Amarin Corporation plc?
Analysts covering Amarin Corporation plc (AMRN) range from a bear-case target of $12.00 to a bull-case high of $13.00, with a mean consensus target of $12.50 across 2 analysts. The spread of $1.00 (8% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Amarin Corporation plc against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Amarin Corporation plc
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full AMRN research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Amarin Corporation plc, in minutes. 3 free reports included with every account — no credit card required.